# KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-reports-eight-months-fiscal-year-2025-financial-results-and-provides-corporate-update
Ticker: KALV
Company: KalVista Pharmaceuticals, Inc.
Source: KalVista Pharmaceuticals, Inc.
Published: 2026-03-25 11:00 EST
Original Source URL: https://ir.kalvista.com
## Summary

$49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary

## Article Body
$49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary
## Recent Company News
- 2026-05-28 11:00 EST — [KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-presents-new-data-highlighting-the-burden-of-injectable-on-demand-treatment-in-young-children-with-hereditary-angioedema) — Source: KalVista Pharmaceuticals, Inc.
- 2026-04-29 11:00 EST — [Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio](https://biopharmsignal.com/news/KALV/chiesi-group-to-acquire-kalvista-pharmaceuticals-expanding-its-global-rare-disease-portfolio) — Source: KalVista Pharmaceuticals, Inc.
- 2026-04-08 11:00 EST — [KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: KalVista Pharmaceuticals, Inc.
- 2026-04-02 20:01 EST — [KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: KalVista Pharmaceuticals, Inc.
- 2026-03-30 11:00 EST — [KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-announces-positive-interim-phase-3-data-from-konfident-kid-trial-of-ekterlyr-sebetralstat-for-children-aged-2-11-years-at-the-2026-global-angioedema-leadership-conference) — Source: KalVista Pharmaceuticals, Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)